Abstract

Statin-induced rhabdomyolysis is a rare but important and potentially life-threatening condition characterized by muscle symptoms and an increase in creatine kinase levels. Statin-induced rhabdomyolysis is often caused by the interactions of several drugs metabolized by the CYP450 family, which is why in using polypharmacotherapy it is necessary to evaluate the interactions and side effects of different drugs. Since statin-induced rhabdomyolysis is a fairly rare condition, it is important to recognize its symptoms and identify the condition as being induced by statins. Only then is it possible to stop the treatment with statins and avoid serious complications.